Insights Into Acute Myeloid Leukemia 2020 Northwest

Perspectives from community physicians from the northwest region of the US on current treatment practices regarding therapy of acute myeloid leukemia and attitudes toward recently introduced and upcoming agents

Northwest – October 29, 2020

Faculty Chair

Farhad Ravandi, MD

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Example Report

Start discovering the insights

View Report


First-Line Therapy of AML  

  • Overview of current data 
  • Factors guiding first-line therapy 
  • Integration of novel agents approved and under investigation (FLT3 inhibitors, BCL2 inhibitors, Hedgehog pathway inhibitors, IDH1 inhibitors) 
  • Maintenance therapy? 
  • Role of MRD 

 Management of Relapsed/Refractory Disease and Promising Strategies in AML 

  • Overview of current data 
  • Factors guiding second-line and subsequent therapy 
  • Promising agents 


  • A moderated virtual roundtable discussion focusing on treatment of AML was held October 29, 2020
  • The group of advisors comprised 8 community oncologists from the northwest region of the US
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.